Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion

NCT02504489 is registered in ClinicalTrials.gov with BeyondSpring Pharmaceuticals Inc. as lead sponsor.

NCT NCT02504489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02504489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion
Lead sponsor
BeyondSpring Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2015
Completion date
October 30, 2023
Enrollment
559 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer